甲泼尼龙治疗小儿难治性肺炎支原体肺炎的临床疗效分析

doi:10.3969/j.issn.1006-6233.2018.05.036

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (1315 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical efficacy of methylprednisolone in the treatment of children with intractable pneumonia mycoplasma pneumonia. Methods: 200 infants with refractory mycoplasma pneumoniae pneumonia admitted from January 2016 to October 2017 were randomly divided into two groups, the control group received azithromycin, and the observation group received methylprednisolone Group of children with clinical indicators, the overall effect of treatment, disease-related parameters and safety. Results: The cough onset time, cough disappearance time, antipyretic time, wet rales disappear time, wheezing disappearance time and hospitalization time in observation group were significantly lower than those in control group. The 2/3 shadow absorption rate Significantly higher than the control group; the total effective rate was significantly higher than the control group; after treatment, the white blood cell count was significantly higher than the control group, CRP, IL-4, IL-10, IL-17 and TGF- Significantly lower than the control group, there was a significant difference (P <0.05); two groups of children with adverse drug reaction rate was not significantly different (P> 0.05). Conclusion: The clinical efficacy of methylprednisolone in the treatment of pediatric intractable pneumonia mycoplasma pneumonia is significant and has reference value.

Key words： Methylprednisolone Refractory mycoplasma pneumonia Children

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Na
	SUN Daqing

Cite this article:

ZHENG Na,SUN Daqing. Clinical Efficacy of Methylprednisolone in the treatment of Pediatric Intractable Pneumonia Mycoplasma Pneumonia[J]. HeBei Med, 2018, 24(5): 837-840.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.05.036 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I5/837

[1] 陈丽兰.常量甲泼尼龙治疗无效的儿童难治性肺炎支原体肺炎的临床特征和治疗方案探讨[J].河北医学,2016,22(1):147~150.
[2] 曹效红.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效与安全性分析[J].国际医药卫生导报,2016,22(12):1745~1748.
[3] 施湘萍.阿奇霉素联合甲泼尼龙治疗小儿难治性支原体肺炎45例疗效观察[J].中国药业,2017,26(21):48~50.
[4] 吴天桂.阿奇霉素与甲泼尼龙对难治性支原体肺炎患儿的疗效评价[J].抗感染药学,2017,14(1):130~132.
[5] 咸阳,王铁岩,郑纯凤.琥珀酸钠甲泼尼龙联合纤维支气管镜术治疗难治性肺炎支原体肺炎的疗效观察[J].河北医药,2016,38(20):3072~3075.
[6] 荣杰鑫,王亚亭,李远波,等.甲泼尼龙对儿童难治性肺炎支原体肺炎疗效和安全性评价的Meta分析[J].安徽医药,2017,21(9):1688~1693.
[7] 郭平,周德媛.甲泼尼龙辅助治疗儿童难治性肺炎支原体肺炎疗效分析[J].海峡药学,2011,23(12):125~127.
[8] 李小瑜,陈少君,陈雅杏.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎(RMPP)的疗效与安全性[J].北方药学,2017,14(1):151~152.
[9] 卢小蕴,方锦平,夏巧湘.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效及其对相关实验室指标的影响[J].儿科药学杂志,2017,28(9):14~16.
[10] 范徐威.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎(RMPP)的疗效与安全性[J].生物医学工程学进展,2015,36(4):246~248.
[11] 柯丽莉.匹多莫德联合小剂量甲泼尼龙对难治性肺炎支原体肺炎患儿免疫功能及血清炎性细胞因子水平的影响[J].山西医药杂志,2017,46(19):2340~2342.
[12] 李玲.小剂量甲泼尼龙辅助治疗儿童难治性肺炎支原体肺炎疗效观察[J].儿科药学杂志,2015,21(3):18~21.
[13] 赵淑清,赵艳荣.小剂量注射用甲泼尼龙琥珀酸钠冲击治疗对儿童难治性支原体肺炎的效果[J].医学综述,2017,23(4):798~801.